Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck initiates clinical studies for new mood disorder candidate

Lundbeck initiates clinical studies for new mood disorder candidate

4th January 2008

A new pharmaceutical candidate has joined Lundbeck’s development pipeline, the company reports.

Phase I clinical studies have just been launched for the compound Lu AA37096 in order investigate its safety, tolerability and the pharmokinetic profile of the drug in humans.

The compound has already been shown to have a very convincing effect in animal models in relation to mood disorders as well as in pain models.

Lu AA37096 was discovered based on findings generated from the mechanism action of Cipralex (escitalopram) but the candidate incorporates effects on a number of additional targets in the brain.

Peter Hongaard Anderson, head of research at Lundbeck, confirmed that the division was focusing on the discovery of innovative compounds that addressed unmet medical needs.

“Lu AA37096 is an example of a new generation of compounds with a great potential within mood disorders and other indications for which preclinical research has demonstrated significant efficacy,” he added.

The pharmaceutical company has also decided this week to suspend further development of compound Lu AA44608, currently in clinical phase I, for the potential treatment of mood disorders.

Last month, Lundbeck announced an expansion of its licensing agreement with Paion for desmoteplase, a genetically engineered form of a clot-dissolving protein found in the saliva of Desmodus rotundus vampire bats.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.